All In Biotech

Drug Trial Radar · NCT07775924

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess the Efficacy and Safety of GIA632 in Participants With Moderate to Severe Cutaneous Lichen Planus, Followed by an Extension Period

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 259 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

259

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Nov 22, 2028

Study completion Feb 13, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP).

Conditions

  • Cutaneous Lichen Planus

Interventions

  • PlaceboDrug

    Matching placebo

  • GIA632Drug

    GIA632 administered according to the assigned study treatment regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants achieving an Investigator Global Assessment (IGA) responseTime frame: Week 16

Locations

27 sites in 4 countries. Site status is shown where the registry gives one.

  • Cahaba Derm and skin hlth ctr 27

    Birmingham, Alabama · Recruiting

  • First OC Dermatology

    Fountain Valley, California · Recruiting

  • Encore Medical Research

    Hollywood, Florida · Recruiting

  • Miami Derm and Laser Institute

    Miami, Florida · Recruiting

  • Global Clinical Professionals

    St. Petersburg, Florida · Recruiting

  • Skin Care Physicians Of Georgia

    Macon, Georgia · Recruiting

  • Dawes Fretzin Clinical Rea Group

    Indianapolis, Indiana · Recruiting

  • Essential Medical Research

    Overland Park, Kansas · Recruiting

  • Louisiana Dermatology Associates

    Baton Rouge, Louisiana · Recruiting

  • Delricht Research

    New Orleans, Louisiana · Recruiting

  • Uni Of Michigan Health System

    Ann Arbor, Michigan · Recruiting

  • Hamzavi Dermatology

    Fort Gratiot, Michigan · Recruiting

  • Minnesota Clinical Study Center

    New Brighton, Minnesota · Recruiting

  • MediSearch Clinical Trials

    Saint Joseph, Missouri · Recruiting

  • Skin Specialists PC

    Omaha, Nebraska · Recruiting

  • Bellaire Dermatology Associates

    Bellaire, Texas · Recruiting

  • NextGen Clinical Research and Innovation Inc-Network

    Mansfield, Texas · Recruiting

  • Austin Inst for Clinical Research

    Pflugerville, Texas · Recruiting

  • RFSA Dermatology

    San Antonio, Texas · Recruiting

  • Novartis Investigative Site

    Sydney, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Waitara, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    London, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Recruiting

  • Novartis Investigative Site

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.